GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genor Biopharma Holdings Ltd (HKSE:06998) » Definitions » EV-to-EBITDA

Genor Biopharma Holdings (HKSE:06998) EV-to-EBITDA : 0.82 (As of Jun. 03, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Genor Biopharma Holdings EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genor Biopharma Holdings's enterprise value is HK$-604.66 Mil. Genor Biopharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-740.06 Mil. Therefore, Genor Biopharma Holdings's EV-to-EBITDA for today is 0.82.

The historical rank and industry rank for Genor Biopharma Holdings's EV-to-EBITDA or its related term are showing as below:

HKSE:06998' s EV-to-EBITDA Range Over the Past 10 Years
Min: -24.66   Med: 0.71   Max: 1.7
Current: 0.82

During the past 6 years, the highest EV-to-EBITDA of Genor Biopharma Holdings was 1.70. The lowest was -24.66. And the median was 0.71.

HKSE:06998's EV-to-EBITDA is ranked better than
71.9% of 452 companies
in the Biotechnology industry
Industry Median: 9.47 vs HKSE:06998: 0.82

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-03), Genor Biopharma Holdings's stock price is HK$1.29. Genor Biopharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.455. Therefore, Genor Biopharma Holdings's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Genor Biopharma Holdings EV-to-EBITDA Historical Data

The historical data trend for Genor Biopharma Holdings's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genor Biopharma Holdings EV-to-EBITDA Chart

Genor Biopharma Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - -1.79 -1.07 0.52 1.01

Genor Biopharma Holdings Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.07 - 0.52 - 1.01

Competitive Comparison of Genor Biopharma Holdings's EV-to-EBITDA

For the Biotechnology subindustry, Genor Biopharma Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genor Biopharma Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genor Biopharma Holdings's EV-to-EBITDA falls into.



Genor Biopharma Holdings EV-to-EBITDA Calculation

Genor Biopharma Holdings's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-604.661/-740.06
=0.82

Genor Biopharma Holdings's current Enterprise Value is HK$-604.66 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-740.06 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genor Biopharma Holdings  (HKSE:06998) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Genor Biopharma Holdings's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.29/-1.455
=At Loss

Genor Biopharma Holdings's share price for today is HK$1.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.455.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Genor Biopharma Holdings EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genor Biopharma Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genor Biopharma Holdings (HKSE:06998) Business Description

Traded in Other Exchanges
Address
1690 Zhangheng Road, Building 3, Pudong New District, Shanghai, CHN, 201203
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates include GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), a novel PD-1 mAb drug candidate; GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL mAb drug candidate.
Executives
Hillhouse Investment Management, Ltd. 2102 Investment manager
Hhjh Holdings Limited 2101 Beneficial owner
Hillhouse Fund Iv, L.p. 2201 Interest of corporation controlled by you
Hh Bio Investment Fund, L.p. 2201 Interest of corporation controlled by you
Hillhouse Capital Management, Ltd. 2102 Investment manager
Hh Bio Investment Fund L.p. 2201 Interest of corporation controlled by you
Temasek Capital (private) Limited
Aranda Investments Pte. Ltd.
Seletar Investments Pte Ltd
Walga Biotechnology Limited 2101 Beneficial owner
Shang Hai Wo Jia Sheng Wu Ji Shu You Xian Gong Si 2201 Interest of corporation controlled by you
Yun Nan Wo Sen Sheng Wu Ji Shu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Temasek Holdings (private) Limited

Genor Biopharma Holdings (HKSE:06998) Headlines

No Headlines